Xyrem gains daytime claim
FDA clears Jazz Pharmaceuticals' Xyrem (sodium oxybate) for treatment of excessive daytime sleepiness in patients with narcolepsy Nov. 18. Xyrem was previously approved for cataplexy in narcolepsy patients. The firm has said that it would seek a general narcolepsy indication; cataplexy and EDS are the two primary symptoms of narcolepsy (1"The Pink Sheet" April 25, 2005, p. 26)...
You may also be interested in...
Jazz Pharmaceuticals is likely to experiment with new formulations of the narcolepsy agent Xyrem (sodium oxybate) after acquiring Orphan Medical
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.